Zeaxanthin
Also known as: Lutein + Zeaxanthin (often paired), 3,3'-Dihydroxy-β,β-carotene
Large randomized trials (AREDS2 and follow-up analyses) and systematic reviews provide the main human evidence. Primary AREDS2 analyses did not show a statistically significant reduction in progression to advanced AMD with lutein/zeaxanthin versus placebo over ~5 years, but longer-term follow-up and secondary/post hoc analyses indicate modest reductions in risk of late AMD and slower progression of geographic atrophy toward the fovea in some analyses.
Last reviewed: 2026-10-14 · 5 indexed studies
Set your location for accurate regulatory status
Saved on this device — no sign-in needed.
Overview
Zeaxanthin is a dietary xanthophyll carotenoid found in the macula of the retina and commonly supplemented together with lutein. Human trials have evaluated oral lutein/zeaxanthin supplements for slowing progression of age-related macular degeneration (AMD), typically at 10 mg lutein + 2 mg zeaxanthin daily.
Mechanism & Function
Mechanism of Action
Zeaxanthin accumulates in the macula where it contributes to macular pigment and may filter blue light and act as an antioxidant, potentially protecting retinal tissue from oxidative damage implicated in AMD progression.
Physiological Role
Constituent of macular pigment; absorbs short-wavelength light and has antioxidant activity in retinal tissue.
Primary Pathways
Performance / Health Relevance
Evidence relates specifically to slowing progression of age-related macular degeneration and reducing risk of late AMD in people with existing intermediate disease; not shown to improve visual acuity in the general population in these abstracts.
Evidence Review
Practical Use & Dosage
- Minimum Effective Dose
- 10 mg lutein + 2 mg zeaxanthin daily (dose used in AREDS2 trials)
- Optimal Range
- 10 mg lutein + 2 mg zeaxanthin daily (evidence-based; other doses not represented in provided abstracts)
- Upper / Caution Level
- Not established
- Timing
- Daily with a meal (fat-containing meal likely improves absorption)
- Best Format
- Oral capsule/softgel combined with dietary fat for absorption
- Bioavailability
- Absorption of carotenoids is enhanced when taken with dietary fat; commonly formulated with oils.
- Absorption Considerations
- Take with food containing fat to improve uptake; co-administration with multivitamin/mineral formulations was used in trials.
Safety & Interactions
Side Effects
- •Generally well tolerated in trials reported here (no treatment-specific adverse safety signals for lutein/zeaxanthin in the provided abstracts)
- •Note: β-carotene (a different carotenoid) was associated with increased lung cancer risk in smokers in AREDS-related data; this was the rationale for replacing β-carotene with lutein/zeaxanthin
Contraindications
- No specific contraindications reported in the provided abstracts
Drug Interactions
- •None reported in the provided abstracts
Who Should Avoid
- •Current evidence does not identify groups who must avoid lutein/zeaxanthin; β-carotene should be avoided by current smokers based on AREDS data (different compound)
Monitoring
Monitor for clinical progression of AMD as per ophthalmology guidance; safety monitoring in trials did not flag lutein/zeaxanthin-specific harms in the provided abstracts.
Frequently Asked Questions
Auto-generated from indexed evidence — dosage, safety, interactions, and more.
When is Zeaxanthin typically used or indicated?
Zeaxanthin is most commonly used for: Support for age-related macular degeneration (AMD) / eye health, Dietary carotenoid supplementation, General antioxidant support targeted to the retina. Constituent of macular pigment; absorbs short-wavelength light and has antioxidant activity in retinal tissue.
How does Zeaxanthin work?
Zeaxanthin accumulates in the macula where it contributes to macular pigment and may filter blue light and act as an antioxidant, potentially protecting retinal tissue from oxidative damage implicated in AMD progression.
What is the recommended dose of Zeaxanthin?
The optimal range is 10 mg lutein + 2 mg zeaxanthin daily (evidence-based; other doses not represented in provided abstracts). with a minimum effective dose of 10 mg lutein + 2 mg zeaxanthin daily (dose used in AREDS2 trials). Best taken: Daily with a meal (fat-containing meal likely improves absorption). Upper / caution level: Not established.
What are the side effects of Zeaxanthin?
Reported side effects include: Generally well tolerated in trials reported here (no treatment-specific adverse safety signals for lutein/zeaxanthin in the provided abstracts); and Note: β-carotene (a different carotenoid) was associated with increased lung cancer risk in smokers in AREDS-related data; this was the rationale for replacing β-carotene with lutein/zeaxanthin. Monitoring: Monitor for clinical progression of AMD as per ophthalmology guidance; safety monitoring in trials did not flag lutein/zeaxanthin-specific harms in the provided abstracts.
Does Zeaxanthin interact with medications?
Known or theoretical interactions: None reported in the provided abstracts. Always check with a clinician before combining with prescription medication.
Who should avoid Zeaxanthin?
Zeaxanthin is generally not recommended for: Current evidence does not identify groups who must avoid lutein/zeaxanthin; β-carotene should be avoided by current smokers based on AREDS data (different compound); and No specific contraindications reported in the provided abstracts.
How strong is the evidence for Zeaxanthin?
Evidence level: Moderate (overall score 65/100), based on 5 indexed studies on SuppIndex.
Research & References (5)
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
AREDS2 randomized 4203 participants at risk for progression to advanced AMD to lutein (10 mg) + zeaxanthin (2 mg), ω-3 fatty acids, both, or placebo, with median follow-up 5 years.
Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.
Ten-year epidemiologic follow-up of AREDS2 participants assessed long-term risk of late AMD and lung cancer after randomization to lutein/zeaxanthin and/or ω-3 fatty acids during the trial.
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
Cochrane systematic review of antioxidant vitamin and mineral supplements for slowing AMD progression including AREDS/AREDS2 data and 26 trials overall.
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.
Post hoc analyses of AREDS and AREDS2 examined whether oral antioxidant and lutein/zeaxanthin supplements slow geographic atrophy (GA) progression toward the fovea.
The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).
AREDS2 study design and baseline characteristics; describes randomization to lutein/zeaxanthin 10 mg/2 mg and trial structure.
Related Ingredients
Other top-rated ingredients in General Health Ingredients.
Piperine
82/100A piperidine alkaloid (C₁₇H₁₉NO₃) that inhibits cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2E1), P-glycoprotein efflux transporters, and UDP-glucuronosyltransferases while enhancing intestinal permeability, digestive enzyme secretion, and splanchnic blood flow — collectively producing dramatic improvements in nutrient bioavailability.
CoQ10
78/100Endogenous lipid-soluble ubiquinone/ubiquinol that shuttles electrons in the mitochondrial respiratory chain and acts as a membrane antioxidant.
Beta-Glucan (Oat)
77/100Multiple randomized trials and meta-analyses report that ≥3 g/day oat beta-glucan lowers LDL and total cholesterol modestly. Acute feeding trials pooled in meta-analysis show dose- and molecular-weight–dependent reductions in postprandial glucose and insulin responses.
Research Overview
Moderate EvidenceCite this ingredient
One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.
Stable URL
https://thesuppindex.com/ingredients/zeaxanthin
SuppIndex. (2026). Zeaxanthin: Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/zeaxanthin
Based on 5 indexed studies · Evidence level: Moderate.
Goal Ratings
Stack Compatibility
Studied within the AREDS/AREDS2 formulations alongside antioxidant vitamins and minerals; commonly used in multinutrient eye supplements.